Long non‐coding RNA 00312 regulated by HOXA5 inhibits tumour proliferation and promotes apoptosis in Non‐small cell lung cancer. Issue 9 (24th March 2017)

• Record Type: Journal Article
• Authors: Zhu, Qingqing; Lv, Tangfeng; Wu, Ying; Shi, Xuefei; Liu, Hongbing; Song, Yong
• Is Part Of: Journal of cellular and molecular medicine. Volume 21:Issue 9(2017)
• Page Start: 2184
• Page End: 2198
• Publication Date: 2017-03-24
• Subjects: NCSLC -- lncRNA -- linc00312 -- HOXA5 -- proliferation -- apoptosis; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13142
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Non‐small cell lung cancer (NSCLC) is the most prevalent type of lung cancer. The abnormal expression of many long non‐coding RNAs (lncRNAs) has been reported involved in the progression of various tumours, which can be used as diagnostic indicators or antitumour targets. Here, we found that the long non‐coding RNA 00312 was down‐regulated in paired NSCLC tissues and correlated with poor clinical outcome; decreased linc00312 expression in NSCLC was associated with larger and later stage tumours. Functional experiments showed that linc00312 could inhibit cell proliferation and promote apoptosis in vitro and in vivo . Furthermore, we found that HOXA5 could bind in the promoter of linc00312 and up‐regulated the expression of it. Moreover, linc00312 was down‐regulated in the plasma of NSCLC patients compared with that of healthy volunteers or other pulmonary diseases patients. Taken together, our findings indicated that linc00312 could be a novel diagnosis biomarker and a promising therapeutic target for NSCLC.